IP Library Granted Patent US 7,183,045
Granted Patent B2
US 7,183,045 · App. 10/423,200 · Granted Feb 27, 2007

Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,045
App. No.
10/423,200
Granted
Feb 27, 2007
Kind
B2
Abstract

The methods of this invention involve preventing the formation of a complex between adenine and riboflavin by reducing the amount of adenine in a solution containing blood or blood components to be pathogen reduced.

Claims (8)

1. A method for treating a selected quantity of fluid comprising whole blood to reduce pathogens which may be present therein, the method comprising:

(a) reducing the concentration of adenine in the selected quantity of fluid by adding a sufficient volume of a diluting solution to the selected quantity of fluid;

(b) mixing a pathogen reduction-effective, substantially non-toxic amount of 7,8-dimethyl-10-ribityl isoalloxazine photosensitizer with the fluid;

(c) exposing the fluid containing the photosensitizer to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby the pathogens are reduced.

2. A method for treating a selected quantity of fluid to reduce pathogens which may be present wherein the fluid consists essentially of red blood cells, the method comprising:

(a) reducing the concentration of adenine in the selected quantity of fluid by adding a sufficient volume of a diluting solution to the selected quantity of fluid;

(b) mixing a pathogen reduction-effective, substantially non-toxic amount of 7,8-dimethyl-10-ribityl isoalloxazine photosensitizer with the fluid;

(c) exposing the fluid containing the photosensitizer to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby the pathogens are reduce.

Assignments (3)
CHANGE OF NAME Recorded Feb 16, 2012
From: CARIDIANBCT BIOTECHNOLOGIES, LLC.
To: TERUMO BCT BIOTECHNOLOGIES, LLC
Reel/Frame 027715/0552 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: CARIDIANBCT BIOTECHNOLOGIES, LLC
Reel/Frame 026192/0547 →
IP SECURITY AGREEMENT SUPPLEMENT Recorded May 21, 2009
From: CARIDIANBCT BIOTECHNOLOGIES, LLC
To: CITICORP TRUSTEE COMPANY LIMITED
Reel/Frame 022714/0560 →